Evidence map›Paper›PMID 40118539›Full record

ArticleJournal of the American Board of Family Medicine : JABFM

The Effects of Testosterone on Cervicovaginal Cytology in Transgender and Gender-Diverse Individuals.

Derek Chen, Jeremy Erroba, Shuling Liu, Tahlia Hodes, Heather Holderness, Nathalie Huguet, Christina Milano

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Board of Family Medicine : JABFM. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Derek ChenFrom the Oregon Health & Science University, Department of Oregon Health & Science University, Department of Family Medicine, Portland (DC, JE, SL, TH, HH, NH, CM); Icahn School of Medicine at Mount Sinai, New York, NY (DC); Transgender Health Program, Oregon Health & Science University, Portland (CM). derek.chen@icahn.mssm.edu.
Jeremy ErrobaFrom the Oregon Health & Science University, Department of Oregon Health & Science University, Department of Family Medicine, Portland (DC, JE, SL, TH, HH, NH, CM); Icahn School of Medicine at Mount Sinai, New York, NY (DC); Transgender Health Program, Oregon Health & Science University, Portland (CM).
Shuling LiuFrom the Oregon Health & Science University, Department of Oregon Health & Science University, Department of Family Medicine, Portland (DC, JE, SL, TH, HH, NH, CM); Icahn School of Medicine at Mount Sinai, New York, NY (DC); Transgender Health Program, Oregon Health & Science University, Portland (CM).
Tahlia HodesFrom the Oregon Health & Science University, Department of Oregon Health & Science University, Department of Family Medicine, Portland (DC, JE, SL, TH, HH, NH, CM); Icahn School of Medicine at Mount Sinai, New York, NY (DC); Transgender Health Program, Oregon Health & Science University, Portland (CM).
Heather HoldernessFrom the Oregon Health & Science University, Department of Oregon Health & Science University, Department of Family Medicine, Portland (DC, JE, SL, TH, HH, NH, CM); Icahn School of Medicine at Mount Sinai, New York, NY (DC); Transgender Health Program, Oregon Health & Science University, Portland (CM).
Nathalie HuguetFrom the Oregon Health & Science University, Department of Oregon Health & Science University, Department of Family Medicine, Portland (DC, JE, SL, TH, HH, NH, CM); Icahn School of Medicine at Mount Sinai, New York, NY (DC); Transgender Health Program, Oregon Health & Science University, Portland (CM).
Christina MilanoFrom the Oregon Health & Science University, Department of Oregon Health & Science University, Department of Family Medicine, Portland (DC, JE, SL, TH, HH, NH, CM); Icahn School of Medicine at Mount Sinai, New York, NY (DC); Transgender Health Program, Oregon Health & Science University, Portland (CM).

Funding

Research ProgramP50CA244289 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI HUGUET, NATHALIE · 2019 to 2023
$7.6M
NCI NIH HHS P50 CA244289
6 · The paper itself

Abstract

backgroundThe Papanicolaou (Papanicolaou) test is an effective and widely used cervical cancer screening procedure. Recommendations for cervical cancer screening do not incorporate patients' gender identities nor gender-affirming hormone statuses in determining screening surveillance intervals and interpreting test results. This study assessed the association between testosterone and rates of abnormal Papanicolaou specimens and specimen adequacy by comparing testosterone-associated Papanicolaou specimens and nontestosterone Papanicolaou specimens among transgender and gender-diverse (TGD) patients.

methodsRetrospective electronic health record chart review of 211 TGD patients with cervixes, contributing 298 unique Papanicolaou tests, with a visit to a primary care clinic between 2012 and 2019. Primary outcomes included specimen quality (transformation zone [TZ] present, TZ absent, atrophic specimen, scant cellularity), presence of inflammation (yes/no), and cytology results (normal, abnormal, inadequate specimen). χ

resultsA higher proportion of TAPS had missing TZ, showed atrophy, or had scant cellularity than NTPS (58.8% vs 33.5%;

conclusionsFindings confirmed an association between testosterone usage and cytology specimen adequacy and quality. No association was found between testosterone usage and rates of abnormal results within our TGD population. More research is needed to disentangle the effect of missing TZ on risk of future cervical dysplasia among this younger population.

Indexed as

Cervix UteriPapanicolaou TestTestosteroneTransgender PersonsUterine Cervical NeoplasmsVaginal SmearsAdultEarly Detection of CancerFemaleHumansMaleMiddle AgedRetrospective StudiesTestosteroneCancer ScreeningCervical CancerGender IdentityHormone Replacement TherapyPapanicolaou TestPrimary Health CareRetrospective StudiesTestosterone

Identifiers

PMID40118539
PMCPMC12498294

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.